(Q34548300)

2 August 2017

Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites (English)

1 reference

2 August 2017

Vassilakopoulos TP

1

1 reference

2 August 2017

Angelopoulou MK

2

1 reference

2 August 2017

Siakantaris MP

3

1 reference

2 August 2017

Kontopidou FN

4

1 reference

2 August 2017

Dimopoulou MN

5

1 reference

2 August 2017

Barbounis A

6

1 reference

2 August 2017

Grigorakis V

7

1 reference

2 August 2017

Karkantaris C

8

1 reference

2 August 2017

Anargyrou K

9

1 reference

2 August 2017

Chatziioannou M

10

1 reference

2 August 2017

Rombos J

11

1 reference

2 August 2017

Boussiotis VA

12

1 reference

2 August 2017

Vaiopoulos G

13

1 reference

2 August 2017

Kittas C

14

1 reference

2 August 2017

Pangalis GA

15

1 reference

2 August 2017

1 November 2001

1 reference

2 August 2017

10

1 reference

European Journal of Haematology

inferred from page(s)

published in

1 reference

2 August 2017

67

1 reference

2 August 2017

279-288

1 reference

2 August 2017

5-6

1 reference

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

2 August 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Hodgkin's disease prognosis: a directly predictive equation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curi

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Treatment of relapsed Hodgkin's disease: strategies and prognostic factors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

The significance of mediastinal involvement in early stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Tumour burden as the main indicator of prognosis in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Conceptual problems in relation to dose escalation in the first remission of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00561.X

7 January 2021

10.1034/J.1600-0609.2001.00561.X

Identifiers

DOI

1 reference

2 August 2017

1 reference